Patents Assigned to Licentia Ltd
-
Patent number: 8029984Abstract: The invention provides materials and methods for colorectal cancer screening, diagnosis, and therapy.Type: GrantFiled: August 6, 2004Date of Patent: October 4, 2011Assignee: Licentia, Ltd.Inventors: Kari Alitalo, Tatiana Petrova, Antti Nykanen
-
Publication number: 20110212091Abstract: The invention provides an isolated antibody or antibody fragment thereof that binds an extracellular epitope of a fibroblast growth factor receptor-4 (FGFR4) that is expressed by mammalian cells and inhibits cancer cell invasion. Optionally, the antibody or fragment thereof binds an epitope of FGFR4 that is bound by monoclonal antibody F90-10C5, or comprises complementarity determining regions identical to those of monoclonal antibody F90-10C5. Also provided are methods of using the antibody or fragment thereof to modulate invasion, ingrowth, or metastasis of cancer cells and treat cancer in a subject. The invention additionally provides a method of identifying an antibody or antibody fragment that inhibits invasiveness.Type: ApplicationFiled: September 2, 2009Publication date: September 1, 2011Applicant: LICENTIA LTD.Inventors: Kari Alitalo, Kaisa Lehti, Jorma Keski-Oja, Annamari Alitalo
-
Publication number: 20110123572Abstract: The invention provides activated fibroblasts for the treatment of tissue and/or organ damage in a patient. Fibroblasts are activated by culturing the cells under conditions that induce the cells to adhere to each other and simultaneously to secrete growth factors, especially hepatocyte growth factor, HGF. The invention also provides a pharmaceutical composition based on the medium in which the activated fibroblasts are cultured. The invention further provides methods for transplantation.Type: ApplicationFiled: August 16, 2007Publication date: May 26, 2011Applicant: Licentia Ltd.Inventors: Jozef Bizik, Ari Harjula, Esko Kankuri, Antti Vaheri
-
Publication number: 20100285045Abstract: The present invention discloses a novel neurotrophic factor protein, MANF2 and a genetic sequence encoding the same. The molecule will be useful in the development of a range of therapeutics and diagnostics useful in the treatment, prophylaxis and/or diagnosis of MANF2 dependent conditions. The molecule of the present invention is also a useful effector of primary and central neurons, especially dopaminergic neurons at the central nervous system and growth factor genes.Type: ApplicationFiled: December 14, 2006Publication date: November 11, 2010Applicant: Licentia LtdInventors: Mart Saarma, Juha Lauren, Paivi Lindholm, Tonis Timmusk, Raimo Tuominen, Merja Voutilainen
-
Publication number: 20100279281Abstract: The present invention is related to a method for assessing the presence of, or disposition to, an asbestos-related disorder in a subject. Particularly, the invention provides a method of identifying lung cancers associated with asbestos-exposure. The association is confirmed by the detection of allelic imbalance (AI) in at least one of the following chromosomal regions of lung cancer cells: 19p13.3-p13.1; 9q32-34.3; 2p21-p16.3; 16p13.3; 22q12.3-q13.1; and 5q35.3.Type: ApplicationFiled: January 18, 2007Publication date: November 4, 2010Applicant: LICENTIA LTD.Inventors: Sisko Anttila, Sakari Knuutila, Jaakko Hollmen, Salla Ruosaari, Harriet Wikman-Kocher, Penny Nymark
-
Publication number: 20100159458Abstract: The present invention relates to cancer treatment and particularly to a method for predicting the response of a cancer subject to a given therapy. The invention provides a gene or gene product useful as a predictive marker for classifying the subjects. Also disclosed are diagnostic tools, test kits and compositions and their use in the method. The invention is based on the use of NAD(P)H:Quinone oxidoreductase 1, NQO1, which enables the identification and classification of subjects who would benefit from being excluded from a treatment, particularly from anthracycline-based adjuvant chemotherapy with epirubicin.Type: ApplicationFiled: November 23, 2007Publication date: June 24, 2010Applicant: Licentia Ltd.Inventors: Heli Nevanlinna, Rainer Fagerholm, Johanna Tommiska
-
Publication number: 20090282495Abstract: The present invention generally relates to the field of treatment of neuronal disorders and more particularly to neurotrophic factor MANF and uses thereof. The present invention provides a pharmaceutical compound comprising MANF nucleic acid molecule, MANF protein or a functional fragment thereof for the treatment of a peripherial neuropathy including Alzheimer's disease, Parkinson's disease, epilepsy, drug addiction and ischemic brain injury.Type: ApplicationFiled: April 30, 2009Publication date: November 12, 2009Applicant: LICENTIA LTD.Inventors: MART SAARMA, PAIVI LINDHOLM, MERJA VOUTILAINEN, JOHAN PERÄNEN, RAIMO TUOMINEN, MIKKO AIRAVAARA, VELI-MATTI LEPPÄNEN, MARIA LINDAHL, JAAN-OLLE ANDRESSOO
-
Publication number: 20090214496Abstract: The present invention relates to materials and methods for the treatment of arterial diseases having impaired arteriogenesis and angiogenesis. More particularly, the invention provides materials and methods for treating arterial disease using a gene therapy vector expressing Bmx tyrosine kinase.Type: ApplicationFiled: January 30, 2007Publication date: August 27, 2009Applicants: LICENTIA LTD., YALE UNIVERSITYInventors: Kari Alitalo, Wang Min
-
Patent number: 7572616Abstract: The invention relates to a method for combating disorders affecting the mitochondrial oxidative phosphorylation system by allotopic expression of the cyanide-insensitive alternative oxidase (AOX) in human cells. The successful expression of AOX in human cells and in Drosophila has been shown to confer spectacular cyanide-resistance to mitochondrial substrate oxidation, alleviate oxidative stress, apoptosis susceptibility and metabolic acidosis. AOX is well tolerated when expressed ubiquitously in the whole organism. AOX expression is a valuable tool to limit the deleterious consequences of respiratory chain deficiency.Type: GrantFiled: November 1, 2006Date of Patent: August 11, 2009Assignees: Licentia Ltd., INSERM (Institut National de la Sante et de la Recherche Medicale)Inventors: Pierre Jean Frederic Rustin, Howard T. Jacobs, Emmanuel Philippe Dassa, Gerrit A J Hakkaart, Daniel Jose Moreno Fernandez-Ayala
-
Publication number: 20090156611Abstract: The disclosure relates to compositions for and methods of inhibiting the mammalian Hedgehog signaling pathway.Type: ApplicationFiled: November 10, 2006Publication date: June 18, 2009Applicant: Licentia Ltd.Inventors: Antti Oinas, Jussi Taipale, Juhani Lahdenperä
-
Patent number: 7488588Abstract: The present invention discloses purified and isolated nucleic acid sequences encoding polypeptides having a structure substantially similar to that of splicing forms of mammalian GFR?4 comprising the amino acid sequence (SEQ ID NO:1:)-(SEQ ID NO:6:). The preferred sequences comprise cDNAs having the sequence (SEQ ID NO:7:)-(SEQ ID NO:13:). The present invention is also related to purified and isolated polypeptides comprising the amino acid sequence and or substantially similar splicing forms of mammalian GFRà4. Furthermore, the invention is related to substances capable of specifically recognizing said polypeptides and including both antibodies and receptors. The active compounds of the present invention including cDNAS, polypeptides, binding substances, and antibodies.Type: GrantFiled: November 14, 2000Date of Patent: February 10, 2009Assignee: Licentia Ltd.Inventors: Matti Airaksinen, Mart Saarma, Dimitri Poteriaev, Maria Lindahl, Tönis Timmusk, Jari Rossi
-
Patent number: 7452969Abstract: The present invention discloses a novel neurotrophic factor protein, MANF2 and a genetic sequence encoding the same. The molecule will be useful in the development of a range of therapeutics and diagnostics useful in the treatment, prophylaxis and/or diagnosis of MANF2 dependent conditions. The molecule of the present invention is also a useful effector of primary and central neurons, especially dopaminergic neurons at the central nervous system and growth factor genes.Type: GrantFiled: August 27, 2003Date of Patent: November 18, 2008Assignee: Licentia LtdInventors: Mart Saarma, Juha Lauren, Päivi Lindholm, Tonis Timmusk, Raimo Tuominen
-
Publication number: 20080269154Abstract: The present invention discloses a novel neurotrophic factor protein, MANF2 and a genetic sequence encoding the same. The molecule will be useful in the development of a range of therapeutics and diagnostics useful in the treatment, prophylaxis and/or diagnosis of MANF2 dependent conditions. The molecule of the present invention is also a useful effector of primary and central neurons, especially dopaminergic neurons at the central nervous system and growth factor genes.Type: ApplicationFiled: February 26, 2008Publication date: October 30, 2008Applicant: Licentia Ltd.Inventors: Mart SAARMA, Juha Lauren, Paivi Lindholm, Tonis Timmusk, Raimo Tuominen
-
Publication number: 20080241178Abstract: The present invention describes a novel human gene, DYXC1, which is functionally related to dyslexia. DYXC1 gene encodes a 420-amino acid residue protein. DYXC1 is expressed in several tissues, including the brain, and is localized in the nucleus. In addition, four single nucleotide polymorphisms (SNPs) in DYXC1 mRNA have been characterized in this invention. The invention provides diagnostic methods and materials for analysing allelic variation in DYSC1 gene. This invention also provides polypeptides encoded by DYXC1 gene and antibodies binding to said polypeptides.Type: ApplicationFiled: March 10, 2008Publication date: October 2, 2008Applicant: Licentia Ltd.Inventors: Juha KERE, Mikko Taipale, Jaana Nopola-Hemmi, Nina Kaminen
-
Publication number: 20080241818Abstract: The present invention relates to a method and to a microarray for detecting herpesviruses. The invention provides new primers and oligonucleotides for detecting herpesviruses, in particular herpesviruses selected from the group comprising HSV-1, HSV-2, CMV, EBV, VZV, HHV-6A, HHV-6B and HHV-7. By using the method of the invention several different herpesviruses can be detected simultaneously from the same biological sample.Type: ApplicationFiled: July 19, 2007Publication date: October 2, 2008Applicant: Licentia Ltd.Inventors: Maija Lappalainen, Antti Vaheri, Anne Jaaskelainen, Heli Piiparinen
-
Publication number: 20080241142Abstract: The present invention relates to identifying modulators of VEGF-C or VEGF-D ligand binding to the nervous system transmembrane protein neuropilin-2 and materials and methods for detecting said modulators.Type: ApplicationFiled: November 29, 2007Publication date: October 2, 2008Applicant: LICENTIA LTD.Inventors: Kari Alitalo, Marika Karkkainen, Kaisa Karila
-
Publication number: 20080241168Abstract: The present invention provides methods and compositions relating to vertebrate AMIGO, AMIGO2, AMIGO3, collectively vertebrate AMIGO polypeptides, related nucleic acids, and polypeptide domains thereof having vertebrate AMIGO-specific structure and activity, and modulators of vertebrate AMIGO function.Type: ApplicationFiled: March 18, 2008Publication date: October 2, 2008Applicant: Licentia Ltd.Inventors: Juha Kuja-Panula, Marjaana Kiiltomaki, Heikki Rauvala
-
Patent number: 7414023Abstract: The present invention relates to novel peptide ligands for prostate specific antigen (PSA) binding specifically with it and enhancing its enzyme activity, to a process for preparation of these peptides, to diagnostic and pharmaceutical compositions comprising these peptides, to the use of these peptides for pharmaceutical and research preparations, to methods using these peptides in diagnostic assays for determination of the concentrations of various molecular forms of PSA, to methods for modulating the PSA enzyme activity and PSA activity dependent conditions by using these peptides either in vivo or in vitro and to the use of these peptides in procedures for biochemical isolation and purification of PSA.Type: GrantFiled: October 1, 2001Date of Patent: August 19, 2008Assignee: Licentia Ltd.Inventors: Stenman Ulf-Hakan, Erkki Koivunen, Jari Leinonen, Ale Närvänen
-
Publication number: 20080145366Abstract: VEGF-D, a new member of the PDGF family of growth factors, which among other things stimulates endothelial cell proliferation and angiogenesis and increases vascular permeability, as well as nucleotide sequences encoding it, methods for producing it, antibodies and other antagonists to it, transfected or transformed host cells for expressing it, pharmaceutical compositions containing it, and uses thereof in medical and diagnostic applications.Type: ApplicationFiled: March 28, 2007Publication date: June 19, 2008Applicants: Licentia, Ltd.Inventors: Marc G. Achen, Andrew F. Wilks, Steven A. Stacker, Kari Alitalo
-
Publication number: 20080147045Abstract: The present invention provides materials and methods for repairing tissue and using vascular endothelial growth factor C (VEGF-C) genes and/or proteins. Methods and materials related to the use of VEGF-C for the reduction of edema and improvement of skin perfusion is provided. Also provided is are materials and methods for using VEGF-C before, during, and after reconstructive surgery.Type: ApplicationFiled: July 24, 2007Publication date: June 19, 2008Applicants: Licentia Ltd., Ludwig Institute for Cancer ResearchInventors: Kari Alitalo, Anne Saaristo, Marika Karkkainen, Tuomas Tammela, Sirpa Asko-Seljavaara, Seppo Yla-Herttuala, Yulong He